Stay updated on PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial
Sign up to get notified when there's something new on the PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial page.

Latest updates to the PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial page
- Check6 days agoChange Detected ClinicalTrials.gov’s study page revision label was updated to a newer version (v3.5.3) from the previous one (v3.5.2).SummaryDifference0.1%

- Check13 days agoChange DetectedAdded Revision: v3.5.2; Deleted Revision: v3.5.0.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check34 days agoChange Detected- Cosmetic UI adjustments observed (overlay elements and layout tweaks). Core study content such as eligibility criteria, interventions, and primary outcomes remains unchanged.SummaryDifference0.1%

- Check42 days agoChange DetectedA new revision label 'Revision: v3.5.0' was added and the previous label 'Revision: v3.4.3' was removed.SummaryDifference0.1%

- Check49 days agoChange DetectedRevision tag updated to v3.4.3 (v3.4.2 removed) on the page footer.SummaryDifference0.1%

- Check77 days agoChange DetectedRevision: v3.4.2 is now displayed, replacing Revision: v3.4.1, and a government funding status notice was removed with no changes to the trial details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial page.